Skye Bioscience, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Skye Bioscience, Inc. (SKYE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.20 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $2.20M, a 11.15% decline year-over-year.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $1.92M, a 1099.46% increase year-over-year.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $1.83M, a 1677.44% increase year-over-year.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $2.48M, a 1783.42% increase year-over-year.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.32M, a 742.27% increase from fiscal 2023.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $987.51K, a 56.99% increase from fiscal 2022.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $629.03K, a 26.53% decline from fiscal 2021.
- Skye Bioscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $856.21K, a 182.82% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-03-31 | $2.20M 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $8.32M 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $1.92M 10-Q · filed 2025-11-10 | $3.75M derived: sum of 2 quarters · filed 2025-11-10 | $6.23M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $1.83M 10-Q · filed 2024-11-07 | $4.31M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $2.48M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $987.51K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $160.21K 10-Q · filed 2024-11-07 | $263.08K derived: sum of 2 quarters · filed 2024-11-07 | $394.66K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $102.87K 10-Q · filed 2024-11-07 | $234.45K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $131.58K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $629.03K 10-K · filed 2024-03-22 | |||
| 2022-09-30 | $144.12K 10-Q · filed 2023-11-14 | $288.49K derived: sum of 2 quarters · filed 2023-11-14 | $438.85K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $144.36K 10-Q · filed 2023-11-14 | $294.72K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $150.36K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $856.21K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $485.72K 10-Q · filed 2022-11-14 | $597.42K derived: sum of 2 quarters · filed 2022-11-14 | $744.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $111.70K 10-Q · filed 2022-11-14 | $258.28K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $146.58K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $302.74K 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $148.37K 10-Q · filed 2021-11-10 | $177.07K derived: sum of 2 quarters · filed 2021-11-10 | $241.22K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $28.71K 10-Q · filed 2021-11-10 | $92.85K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $64.14K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $680.46K 10-K · filed 2021-03-02 | |||
| 2019-09-30 | $170.11K 10-Q · filed 2020-11-06 | $343.19K derived: sum of 2 quarters · filed 2020-11-06 | $514.68K derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $173.08K 10-Q · filed 2020-11-06 | $344.58K derived: sum of 2 quarters · filed 2020-11-06 | ||
| 2019-03-31 | $171.49K 10-Q · filed 2020-11-06 | |||
| 2018-12-31 | $674.96K 10-K · filed 2020-03-23 | |||
| 2018-09-30 | $154.51K 10-Q · filed 2019-11-14 | $255.11K derived: sum of 2 quarters · filed 2019-11-14 | $484.72K derived: sum of 3 quarters · filed 2019-11-14 | |
| 2018-06-30 | $100.60K 10-Q · filed 2019-11-14 | $330.21K derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2018-03-31 | $229.61K 10-Q · filed 2019-11-14 | |||
| 2017-12-31 | $608.68K 10-K · filed 2019-03-14 | |||
| 2016-12-31 | $706.37K 10-K · filed 2018-03-19 | |||
| 2015-12-31 | $351.85K 10-K · filed 2017-03-10 | |||
| 2014-12-31 | $10.77K 10-K · filed 2016-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |